You are viewing: North America Clinical Trial Imaging Market analysis
Part of: Clinical Trial Imaging Market (Global)

The North America Clinical Trial Imaging Market was valued at $74.24 Million in 2024 and projected to reach to $82.66 Million by 2029, representing a compound annual growth rate of CAGR 2.2%. North America's clinical trial imaging market is positioned for steady expansion through 2029, driven by increasing complexity of drug development pipelines and heightened regulatory scrutiny.

North America Clinical Trial Imaging Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America Clinical Trial Imaging Market Trends and Insights

  • This modest but steady expansion reflects Rest Of Europe's increasing investment in clinical research infrastructure and regulatory compliance requirements across multiple therapeutic areas.
  • Rest Of Europe encompasses diverse healthcare systems and research capabilities, with imaging playing a critical role in trial efficacy assessment and patient safety monitoring. The growth trajectory in Rest Of Europe is driven by rising demand for advanced diagnostic imaging technologies in clinical trials, coupled with stricter regulatory frameworks that mandate comprehensive imaging protocols.
  • Rest Of Europe's pharmaceutical and contract research organizations are increasingly adopting digital imaging solutions to enhance trial efficiency and data quality.
  • By 2029, Rest Of Europe is expected to maintain its position as a stable market segment within Europe's broader clinical trial imaging ecosystem, supported by ongoing investments in research facilities and imaging infrastructure modernization..

Key Market Statistics

  • CAGR (2024-2029) CAGR 2.2%
  • Market Size, 2024 ~USD 74.24 Million
  • Forecast, 2029 ~USD 82.66 Million
  • Geography North America

North America Clinical Trial Imaging Market Overview

US Market Dominance :

The United States represents the largest clinical trial imaging market in North America at $734.74 million, driven by advanced healthcare infrastructure, high R&D spending, and FDA regulatory requirements for imaging in drug development.

Canada's Steady Growth :

Canada's clinical trial imaging market valued at $100.17 million demonstrates strong growth potential, supported by robust pharmaceutical research institutions and increasing cross-border clinical trial collaborations with the US.

Regional CAGR Performance :

North America's 2.2% CAGR reflects a mature but stable market with consistent demand from pharmaceutical companies conducting Phase II-IV trials requiring advanced imaging modalities and standardized protocols.

Regulatory Compliance Driver :

Stringent FDA and Health Canada imaging guidelines for clinical trials mandate sophisticated imaging technologies, creating sustained demand for specialized equipment and imaging services across the region.

North America Clinical Trial Imaging Market Dynamics

  • The region benefits from established clinical research infrastructure, significant pharmaceutical R&D investments, and advanced imaging technology adoption across major research centers and contract research organizations. Growth will be supported by rising demand for personalized medicine trials requiring advanced imaging biomarkers, expansion of oncology and neurology trial programs, and integration of AI-powered imaging analytics.
  • While the 2.2% CAGR is modest compared to global rates, it reflects market maturity and consolidation among imaging service providers, with opportunities concentrated in emerging imaging modalities and real-world evidence generation..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Diagnostic Imaging

      Top Technologies
      • Magnetic Resonance Imaging (MRI)
      • Computed Tomography (CT)
      • CT Scanners
      • Nuclear Imaging
      • Positron Emission Tomography
      Top Companies
      • Siemens healthineers
      • PHILIPS HEALTHCARE
      • CANON INC.
      • FUJIFILM Holdings Corporation
      • UNITED IMAGING HEALTHCARE CO., LTD.

        Key Takeaways

        • Rest Of Europe's clinical trial imaging market is valued at $74.24 million in 2024 and will reach $82.66 million by 2029 with a 2.2% CAGR.
        • Rest Of Europe demonstrates steady but conservative growth compared to global markets, reflecting regional regulatory maturity and established research infrastructure.
        • Rest Of Europe's market expansion is supported by increasing adoption of digital imaging technologies and stricter clinical trial compliance requirements.
        • Rest Of Europe's diverse healthcare systems create varied demand for imaging solutions across pharmaceutical, biotech, and contract research organizations.

        Clinical Trial Imaging Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment ONCOLOGY (Therapeutic Area)
        Forecast Period 2024–2029
        Growth Rate CAGR of 7.8% from 2024 to 2029
        Largest Segment SERVICES (Service & Software)
        Market Size Base Year (Billions) ~USD 1.42 (2024)
        Revenue Forecast (Billions) ~USD 2.07 (2029)
        Segments Covered Service & Software, Type, Modality, Therapeutic Area, End User

        North America Clinical Trial Imaging Market Report Segmentation

        5 segment dimensions are covered across the global market.

        By Service & Software

        • Services
        • Software

        By Type

        • Operational Imaging Services
        • Read Analysis Services
        • System And Technical Support Services
        • Trial Design And Consulting Services
        • Trial Design Consulting Services

        By Modality

        • Computed Tomography
        • Magnetic Resonance Imaging
        • Other Modalities
        • Positron Emission Tomography
        • Ultrasound
        • X-Ray

        By Therapeutic Area

        • Cardiovascular System Disorders
        • Endocrinology
        • Immunological Disorders
        • Infectious Diseases
        • Neurology
        • Oncology
        • Other Therapeutic Areas

        By End User

        • Academic And Government Research Institutes
        • Contract Research Organizations
        • Medical Device Manufacturers
        • Other End Users
        • Pharmaceutical & Biotechnology Companies

        Target Audience

        • Pharmaceutical & Biotech Companies : Need market insights to optimize clinical trial imaging budgets, select imaging service providers, and understand regional regulatory requirements for drug development programs.
        • Contract Research Organizations (CROs) : Require detailed market data to benchmark imaging service offerings, identify growth opportunities, and develop competitive strategies in the North American clinical research market.
        • Medical Imaging Equipment Manufacturers : Seek market intelligence on clinical trial imaging demand, technology adoption trends, and opportunities to expand specialized imaging solutions for pharmaceutical research applications.
        • Healthcare Investors & Private Equity : Need comprehensive market analysis to evaluate investment opportunities in clinical imaging service providers, technology platforms, and CRO consolidation strategies in North America.
        • Regulatory & Compliance Consultants : Require market context and regional insights to advise clients on FDA/Health Canada imaging standards, trial design optimization, and compliance best practices for clinical development.

        Key Companies in the North America Clinical Trial Imaging Market

        CompanyHQOwnershipStrongest segments
        PATHEON INCNetherlandsPrivate CompanyDrug product services (finished dosage manufacturing, packaging, lifecycle),Pharmaceutical development services (formulation, analytical, clinical supply),Drug substance services (small- and large-molecule APIs),
        BIOMERIEUX S.A.FrancePublic CompanyClinical microbiology (VITEK, culture media, BACT/ALERT, ETEST, API),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
        TAKE SOLUTIONSIndiaPublic CompanyClinical research and data sciences,Pharmacovigilance, safety, and regulatory affairs,Generics development services,
        BRUKER CORPORATIONUnited StatesPublic CompanyBSI BioSpin (NMR, EPR, preclinical imaging),BSI CALID (mass spectrometry, molecular diagnostics, automation),BSI Nano (X-ray, AFM, electron microscopy tools),
        SANOFIFrancePublic CompanyVaccines (pediatric, RSV, hexavalent, travel),Immunology & Inflammation,Rare Diseases & Neurology,
        MEDIDATA SOLUTIONSUnited StatesPrivate CompanyCore clinical data capture and management (EDC, CTMS, monitoring),Decentralized trial and patient engagement solutions,Data analytics and insights offerings,
        ZENSAR TECHNOLOGIES LTDIndiaPublic CompanyDigital and Application Services,Cloud Infrastructure and Security Services,Brand, Marketing, and Consulting Services,
        TENET HEALTHCARE CORPORATIONUnited StatesPublic CompanyHospital Operations and Services,Ambulatory Care (ASCs and Surgical Hospitals),Other Outpatient and Ancillary Services,
        UNITED IMAGING HEALTHCARE CO., LTD.ChinaPublic CompanyMagnetic Resonance Imaging,Computed Tomography,Molecular Imaging (PET/CT, SPECT),
        ICON PLCIrelandPublic CompanyClinical development services (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory and testing services (bioanalytical, biomarker, central labs, vaccine, GMP),
        MEDPACEUnited StatesPublic CompanyFull-service clinical development (Phase I–IV),Central and bio-analytical laboratory services,Specialized services (imaging, ECG, human pharmacology),
        IXICO PLCUnited KingdomPublic CompanyImaging CRO services (biomarkers, reads, trial management),AI-enabled IXICO platform and data analytics,Post-marketing surveillance, clinical diagnostics, and consultancy,
        RESONANCE HEALTH LTD.AustraliaPublic CompanyFerriScan and CardiacT2 LIC/iron-loading services,AI SaMD (FerriSmart, HepaFatSmart, LiverSmart),HepaFatScan and related liver-fat MRI services,
        WCG CLINICALUnited StatesPrivate CompanyRegulatory and ethical review / human research protections,Technology platforms (eConsent, AIMS, Velos eResearch eXpress),Consulting, biosafety, and online learning,

        PATHEON INC

        Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and life sciences sector.

        BIOMERIEUX S.A.

        bioMérieux S.A. is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.

        TAKE SOLUTIONS

        Take Solutions is an India-based public company founded in 2000 with 2 employees providing business and technology services.

        BRUKER CORPORATION

        Bruker Corporation is a United States-based public company founded in 1960 with 11,085 employees manufacturing scientific instruments and analytical solutions.

        SANOFI

        Sanofi is a French multinational public pharmaceutical company founded in 1994 with 74,846 employees engaged in drug discovery, development, and manufacturing.

        MEDIDATA SOLUTIONS

        Medidata Solutions is a United States-based private company founded in 1999 with 1,998 employees providing cloud-based clinical trial software and services.

        ZENSAR TECHNOLOGIES LTD

        Zensar Technologies Ltd is an India-based public company founded in 1963 with 10,066 employees providing IT services and digital transformation solutions.

        TENET HEALTHCARE CORPORATION

        Tenet Healthcare Corporation is a United States-based public company founded in 1967 with 88,500 employees operating a large network of hospitals and healthcare facilities.

        UNITED IMAGING HEALTHCARE CO., LTD.

        United Imaging Healthcare Co., Ltd. is a China-based public company founded in 2011 with 8,703 employees manufacturing medical imaging equipment and healthcare solutions.

        ICON PLC

        ICON PLC is an Ireland-based public company founded in 1989 with 40,350 employees providing clinical research and drug development services.

        MEDPACE

        Medpace is a United States-based public company founded in 1992 with 6,300 employees offering clinical research and development services.

        IXICO PLC

        IXICO PLC is a United Kingdom-based public company with 79 employees specializing in medical imaging analysis and clinical trial services.

        RESONANCE HEALTH LTD.

        Resonance Health Ltd. is an Australia-based public company founded in 1987 with 16 employees providing medical imaging analysis and software solutions.

        WCG CLINICAL

        WCG Clinical is a United States-based private company founded in 1968 with 1,342 employees providing clinical research and trial management services.

        North America vs. other regions

        HowNorth America compares to the other 3 regional blocs covered in this market.

        Global
        ~USD 393.48 Million · 6.1% wtd CAGR ·
        Europe
        ~USD 315.37 Million · 10.5% wtd CAGR ·
        Asia Pacific
        ~USD 26.81 Million · 5.6% wtd CAGR ·

        Countries within North America - compare and drill down

        Country2025 size (native)
        USUSD 734.74 Million
        CanadaUSD 100.17 Million

        Country market size visualization

        US
        USD 734.74 Million
        Canada
        USD 100.17 Million

        Reasons to Buy this Report

        • Market Size & Forecast Data : Access precise market valuations for North America ($74.24M in 2024, $82.66M by 2029) with country-level breakdowns for US and Canada to support investment decisions and resource allocation.
        • Competitive Landscape Analysis : Understand market consolidation trends, key imaging service providers, and competitive positioning specific to North American clinical research organizations and pharmaceutical companies.
        • Regulatory & Compliance Insights : Gain detailed knowledge of FDA and Health Canada imaging requirements, quality standards, and compliance frameworks driving technology adoption and service demand across the region.
        • Growth Opportunity Identification : Identify high-potential segments including AI-integrated imaging, real-world evidence trials, and emerging therapeutic areas with accelerating clinical development pipelines in North America.
        • Strategic Partnership Intelligence : Leverage market data to identify collaboration opportunities with CROs, imaging centers, and technology providers operating across the US and Canadian clinical trial ecosystems.

        Frequently asked questions

        What is the current size of Rest Of Europe's clinical trial imaging market?

        Rest Of Europe's clinical trial imaging market was valued at $74.24 million in 2024 and is expected to grow to $82.66 million by 2029.

        What is the projected growth rate for Rest Of Europe's clinical trial imaging market?

        Rest Of Europe's clinical trial imaging market is projected to grow at a compound annual growth rate (CAGR) of 2.2% from 2024 to 2029.

        What factors are driving growth in Rest Of Europe's clinical trial imaging market?

        Rest Of Europe's market growth is driven by increased investment in clinical research infrastructure, stricter regulatory compliance requirements, and adoption of advanced digital imaging technologies by pharmaceutical and contract research organizations.

        How does Rest Of Europe's clinical trial imaging market compare to other European regions?

        Rest Of Europe represents a stable market segment within Europe's broader clinical trial imaging ecosystem, with moderate growth reflecting established research infrastructure and regulatory maturity across diverse healthcare systems.

        Which organizations are key participants in Rest Of Europe's clinical trial imaging market?

        Rest Of Europe's clinical trial imaging market includes pharmaceutical companies, biotechnology firms, contract research organizations (CROs), imaging service providers, and healthcare institutions conducting clinical trials across the region.

        RESEARCH METHODOLOGY

        The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the clinical trial imaging market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, market breakdown and data triangulation were used.

        The four steps involved in estimating the market size are:

        Secondary Research

        The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical trial imaging market. A database of the key industry leaders was also prepared using secondary research.

        Primary Research

        The primary research data was conducted after acquiring knowledge about the clinical trial imaging market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals & ICUs, diagnostic laboratories, research institutes, research laboratories and point-of-care settings) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

        A breakdown of the primary respondents is provided below:

        Note 1: *Others include sales managers, marketing managers, and product managers.

        Note 2: Tiers are defined based on a company’s total revenue as of 2022: Tier 1=> USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3=< USD 500 million.

        To know about the assumptions considered for the study, download the pdf brochure

        Market Size Estimation

        All major product manufacturers offering various clinical trial imaging products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value clinical trial imaging market was also split into various segments and subsegments at the region and country level based on:

        • Product mapping of various manufacturers for each type of clinical trial imaging market at the regional and country-level  
        • Relative adoption pattern of each clinical trial imaging market among key application segments at the regional and/or country-level 
        • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level. 
        • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level 

        Data Triangulation

        After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the clinical trial imaging industry.

        Market Definition

        Clinical trial Imaging is used to create images during clinical trials while conducting research. Such imaging testing is mainly done using X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and positron emission tomography (PET). In clinical trials, imaging is used primarily to evaluate efficacy, endpoints, and more frequently, for safety evaluations and eligibility criteria.

        Stakeholders

        • Medical Device Industries
        • Academic and Government Research Institutes
        • Diagnostic Centers
        • Market Research & Consulting Firms
        • Clinical Trial Imaging Manufacturers, Vendors, and Distributors
        • Pharmaceutical and Biotechnology Companies and Contract Research Organizations (CROs)

        Report Objectives

        • To define, describe, segment, and forecast the clinical trial imaging market by service & software, modality, therapeutic area, end user, and region
        • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
        • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
        • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
        • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
        • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
        • To track and analyze company developments such as acquisitions, agreements, partnerships, contracts, approvals, product launches, and mergers in the clinical trial imaging market
        • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product strategy

        Get the Full Clinical Trial Imaging Market Report

        Full forecast, segment splits, and company analysis for all Clinical Trial Imaging Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status